Yuanxin Technology Group Secures Over RMB 1.5 Billion in Series F Funding to Accelerate Digital and Full-Cycle Disease Management Solutions

On August 3, Beijing Yuanxin Technology Group Co., Ltd. (“Yuanxin Technology Group”) completed its Series F financing round, raising over RMB 1.5 billion. The round was jointly invested by HongShan China Fund, Springhill, B Capital Group, Hel Ved, Orbimed, UOB, E Fund, ABI Capital, BOCI, ZhenFund, CITIC Securities, Kunling Capital, Future Qichuang, and Index Capital, with Index Capital continuing to serve as the exclusive financial advisor.

This latest financing round marks another milestone for Yuanxin Technology Group, following its Series D funding in June 2020 and Series E funding in February 2021. Previously, Yuanxin Technology Group’s investor base has included numerous top-tier institutions, with shareholders spanning both primary and secondary markets, the TMT and healthcare sectors, as well as industrial and financial capital. This diverse lineup of premier shareholders undoubtedly reflects a cross-perspective consensus in the capital markets regarding Yuanxin Technology’s significant potential.

It is reported that following this round of financing, Yuanxin Technology Group will further expand its out-of-hospital patient service network and customize post-diagnosis disease management systems for patients with multiple conditions; accelerate the development of its digital hospital network, establish patient service entry points, and provide integrated, full-cycle diagnosis and treatment solutions covering both in-hospital and out-of-hospital settings as well as online and offline channels; further develop commercial health insurance products across multiple disease categories and formats to meet users’ multi-tiered healthcare protection needs; and build IT systems and data frameworks connecting patients, physicians, hospitals, pharmaceutical companies, and insurers, thereby establishing a robust digital infrastructure.

Yuanxin Technology Group, established in 2015, has remained committed to localized doctor-patient connectivity as its core focus. It has gradually developed a business portfolio encompassing Miaoshou Doctor, Yuanxin Pharmacy, Yuanxin Huibao, and Yuanxin Medical Technology, building an efficient service bridge among doctors, pharmaceutical companies, insurance providers, hospitals, and patients.

Currently, the company is building a leading domestic out-of-hospital disease management network and an in-hospital digital smart service network. Leveraging these two interconnected networks, it provides patients with a one-stop solution for medical care, medication, and payment that integrates in-hospital and out-of-hospital services as well as online and offline channels; offers pharmaceutical companies digital-driven solutions for marketing, sales, R&D, and patient management; delivers one-stop service solutions for physicians, including academic exchange, education and training, multi-site practice, and patient management; and provides insurance companies with full-stack operational solutions covering product design, actuarial pricing, loss assessment and surveying, and claims processing.

In the post-pandemic era, the sectors in which Yuanxin Technology Group operates—healthcare, pharmaceuticals, health insurance, and the digital economy—have all become consensus core investment themes in both primary and secondary markets. Amid the continuous evolution of the evergreen healthcare industry, Yuanxin Technology Group has consistently played a leading role, pioneering an innovative development path that integrates “medical care, pharmaceuticals, insurance, and patients,” thereby continuously unlocking and capturing the industry dividends released by transformations in the healthcare system. In this process, Yuanxin Technology Group has continually accumulated key capabilities and core resources, enabling its newly built healthcare value network to sustain rapid growth and firmly establish itself among the industry leaders.